Abbott (ABT) Stock
Diversified global healthcare company with devices and nutrition. Here's the price, business snapshot, and what's worth knowing about Abbott in August 2026.
Abbott Laboratories (ABT) is a diversified global healthcare company operating across diagnostics, medical devices, nutritionals and branded generic pharmaceuticals. With a market capitalisation around $221.98B, Abbott supplies a mix of recurring-revenue products — from diagnostic systems and cardiovascular devices to glucose-monitoring products and infant nutrition — that can offer relative resilience across economic cycles. Investors should note its exposure to regulatory approvals, reimbursement policies and competition from large medtech and pharmaceutical peers, plus currency and supply-chain risks in international markets. Abbott invests in R&D and product upgrades, which can support long-term growth but also requires ongoing capital. The company has historically returned cash to shareholders, yet past distributions do not guarantee future payments. This summary is for general, educational purposes and is not personalised investment advice; individuals should assess suitability, consult up-to-date sources, and consider seeking regulated financial advice before investing.
Why It’s Moving
Abbott gains traction as stronger earnings and litigation clarity sharpen the 2026 outlook
- Abbott’s latest quarter beat expectations, with adjusted EPS and revenue both coming in slightly ahead of estimates, reinforcing confidence in the company’s core diagnostics and medical device businesses.
- Management raised full-year 2026 earnings guidance, signaling that the second-quarter strength may extend into the rest of the year rather than being a one-off boost.
- The company also reached a $670 million settlement tied to infant formula litigation, removing a major legal overhang and giving investors more clarity on a long-running risk.
- Analysts have turned more constructive after the earnings update and litigation clarity, pointing to a cleaner setup for the stock into the second half of 2026.
Abbott gains traction as stronger earnings and litigation clarity sharpen the 2026 outlook
- Abbott’s latest quarter beat expectations, with adjusted EPS and revenue both coming in slightly ahead of estimates, reinforcing confidence in the company’s core diagnostics and medical device businesses.
- Management raised full-year 2026 earnings guidance, signaling that the second-quarter strength may extend into the rest of the year rather than being a one-off boost.
- The company also reached a $670 million settlement tied to infant formula litigation, removing a major legal overhang and giving investors more clarity on a long-running risk.
- Analysts have turned more constructive after the earnings update and litigation clarity, pointing to a cleaner setup for the stock into the second half of 2026.
Sixth Month Growth Performance
next-earnings-question
The next expected earnings date for ABT is October 21, 2026, with the report covering Q3 2026. This aligns with Abbott’s usual late-October third-quarter reporting pattern. If the company changes its schedule, the announcement could shift slightly around that date.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Abbott's stock with a target price of $125.82, indicating potential growth.
Financial Health
Abbott is performing well financially, with strong revenue, cash flow, and profit margins.
Dividend
Abbott's dividend yield of 2.26% offers a decent return for income-seeking investors. If you invested $1000 you would be paid $22.60 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Stable revenue mix
Recurring sales from diagnostics and devices can support steadier cash flows, though performance will vary and is not guaranteed.
Global market reach
A broad international footprint offers growth opportunities but brings currency, regulatory and supply-chain exposure to watch.
Product innovation focus
Ongoing R&D and device upgrades can drive long-term growth, yet new product development faces regulatory and competitive hurdles.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.